205 related articles for article (PubMed ID: 11742860)
1. PPARgamma and atherosclerosis: effects on cell growth and movement.
Hsueh WA; Law RE
Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):1891-5. PubMed ID: 11742860
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Fukunaga Y; Itoh H; Doi K; Tanaka T; Yamashita J; Chun TH; Inoue M; Masatsugu K; Sawada N; Saito T; Hosoda K; Kook H; Ueda M; Nakao K
Atherosclerosis; 2001 Sep; 158(1):113-9. PubMed ID: 11500181
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Collins AR; Meehan WP; Kintscher U; Jackson S; Wakino S; Noh G; Palinski W; Hsueh WA; Law RE
Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):365-71. PubMed ID: 11231915
[TBL] [Abstract][Full Text] [Related]
5. Expression and function of PPARgamma in rat and human vascular smooth muscle cells.
Law RE; Goetze S; Xi XP; Jackson S; Kawano Y; Demer L; Fishbein MC; Meehan WP; Hsueh WA
Circulation; 2000 Mar; 101(11):1311-8. PubMed ID: 10725292
[TBL] [Abstract][Full Text] [Related]
6. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes.
Hsueh WA; Jackson S; Law RE
Diabetes Care; 2001 Feb; 24(2):392-7. PubMed ID: 11213897
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.
de Dios ST; Bruemmer D; Dilley RJ; Ivey ME; Jennings GL; Law RE; Little PJ
Circulation; 2003 May; 107(20):2548-50. PubMed ID: 12742988
[TBL] [Abstract][Full Text] [Related]
8. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
9. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands.
Goetze S; Bungenstock A; Czupalla C; Eilers F; Stawowy P; Kintscher U; Spencer-Hänsch C; Graf K; Nürnberg B; Law RE; Fleck E; Gräfe M
Hypertension; 2002 Nov; 40(5):748-54. PubMed ID: 12411472
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.
Marx N; Schönbeck U; Lazar MA; Libby P; Plutzky J
Circ Res; 1998 Nov; 83(11):1097-103. PubMed ID: 9831704
[TBL] [Abstract][Full Text] [Related]
12. 15-Deoxy-Delta12,14-prostaglandin J2 and thiazolidinediones transactivate epidermal growth factor and platelet-derived growth factor receptors in vascular smooth muscle cells.
Ichiki T; Tokunou T; Fukuyama K; Iino N; Masuda S; Takeshita A
Biochem Biophys Res Commun; 2004 Oct; 323(2):402-8. PubMed ID: 15369766
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic vascular effects of PPARgamma ligands.
Collins AR
Drug News Perspect; 2003 May; 16(4):197-204. PubMed ID: 12942148
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Li AC; Brown KK; Silvestre MJ; Willson TM; Palinski W; Glass CK
J Clin Invest; 2000 Aug; 106(4):523-31. PubMed ID: 10953027
[TBL] [Abstract][Full Text] [Related]
15. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth.
Bruemmer D; Berger JP; Liu J; Kintscher U; Wakino S; Fleck E; Moller DE; Law RE
Eur J Pharmacol; 2003 Apr; 466(3):225-34. PubMed ID: 12694805
[TBL] [Abstract][Full Text] [Related]
16. Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Ishibashi M; Egashira K; Hiasa K; Inoue S; Ni W; Zhao Q; Usui M; Kitamoto S; Ichiki T; Takeshita A
Hypertension; 2002 Nov; 40(5):687-93. PubMed ID: 12411463
[TBL] [Abstract][Full Text] [Related]
17. TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27.
Hupfeld CJ; Weiss RH
Am J Physiol Endocrinol Metab; 2001 Aug; 281(2):E207-16. PubMed ID: 11440895
[TBL] [Abstract][Full Text] [Related]
18. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
Dubois M; Vantyghem MC; Schoonjans K; Pattou F
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
[TBL] [Abstract][Full Text] [Related]
19. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.
Goetze S; Xi XP; Kawano H; Gotlibowski T; Fleck E; Hsueh WA; Law RE
J Cardiovasc Pharmacol; 1999 May; 33(5):798-806. PubMed ID: 10226869
[TBL] [Abstract][Full Text] [Related]
20. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
Diep QN; El Mabrouk M; Cohn JS; Endemann D; Amiri F; Virdis A; Neves MF; Schiffrin EL
Circulation; 2002 May; 105(19):2296-302. PubMed ID: 12010913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
